TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33722855
Drug: OBI-999 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBI-999 (a novel antibody-drug conjugate targeting Globo H)
Study: 33723220
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg over 40 min)
Study: 33723260
Drug: Personalized whole-tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC) combined with bevacizumab (Bev), cyclophosphamide (Cy), acetylsalicylic acid (ASA), and low-dose interleukin (IL)-2
Study: 33723507
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus ivermectin 100 mcg/kg
Study: 33723507
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus ivermectin 200 mcg/kg
Study: 33723507
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus ivermectin 400 mcg/kg
Study: 33723724
Drug: TAS-117 (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-117 (16 mg daily for GI cancers; 24 mg on a 4 days on/3 days off schedule for non-GI cancers)
Study: 33724632
Drug: BAY 94-9027
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 94-9027 (damoctocog alfa pegol); prophylactic treatment twice weekly, every 5 days or every 7 days for ≥50 exposure days.
Study: 33725199
Drug: Current and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current and emerging therapies for cardiac amyloidosis
Study: 33725322
Drug: Ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ropeginterferon alfa-2b (100, 200, 300 µg)
Study: 33725322
Drug: Ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ropeginterferon alfa-2b (up to 300 µg)
Study: 33726819
Drug: Positive end
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive end expiratory pressure titration
Study: 33727862
Drug: Sensitive and
Normalized name: Nivea Sensitive and Radiant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitive and highly sensitive responders to warfarin
Study: 33727862
Drug: Normal responders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal responders to warfarin
Study: 33727901
Drug: sacubitril-valsartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Study: 33727901
Drug: valsartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan (target dose, 160 mg twice daily)
Study: 33728434
Drug: Nonadjuvanted seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted seasonal influenza vaccine
Study: 33728588
Drug: Oral HMAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HMAs
Study: 33728588
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of splicing, CD123/dendritic cell axis, GM-CSF progenitor cell hypersensitivity, JAK/STAT pathway targeting
Study: 33729718
Drug: Checklist for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checklist for Early Recognition and Treatment of Acute Illness and Injury implementation
Study: 33730360
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies (daratumumab, isatuximab, elotuzumab)
Study: 33730360
Drug: Anti-BCMA antibody-drug
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-BCMA antibody-drug conjugate (belantamab mafodotin)
Study: 33730360
Drug: Novel targets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel targets and constructs (bispecific antibodies against BCMA, GPRC5D, FCRH5)
Study: 33730360
Drug: Antibody-based therapy
Normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-based therapy
Study: 33730841
Drug: Bruton's tyrosine
Normalized name: Bruton's tyrosine kinase (BTK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bruton's tyrosine kinase inhibitors
Study: 33730841
Drug: Independent prognostic
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent prognostic impact of treatment, β2-microglobulin and del(17p)
Study: 33730841
Drug: Independent prognostic
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent prognostic impact of treatment, del(11q), del(17p) and SF3B1 mutation
Study: 33730844
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg twice daily until disease progression or intolerance
Study: 33731219
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PAP and mindfulness
Study: 33732892
Drug: μ-opioid agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: μ-opioid agonist buprenorphine
Study: 33732892
Drug: μ-opioid antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: μ-opioid antagonist naltrexone
Study: 33732892
Drug: inert pill
Normalized name: inert ingredients Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: inert pill
Study: 33733443
Drug: Stand-alone Xen45
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stand-alone Xen45 gel stent implantation
Study: 33733980
Drug: Netarsudil ophthalmic
Normalized name: netarsudil ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netarsudil ophthalmic solution 0.02% prescribed once daily
Study: 33733980
Drug: Netarsudil as
Normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Netarsudil as monotherapy
Study: 33733980
Drug: Netarsudil as
Normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Netarsudil as concomitant therapy
Study: 33734088
Drug: C-IPU (clinic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-IPU (clinic-based multidisciplinary therapy)
Study: 33734088
Drug: O-IPU (online
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-IPU (online integrated multidisciplinary therapy)
Study: 33734415
Drug: cRGDY-PEG-Cy5.5-nanoparticles (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: cRGDY-PEG-Cy5.5-nanoparticles (2 nmol, 0.4 mL)
Study: 33734451
Drug: Remote delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote delivery of family-based therapy
Study: 33735176
Drug: Sickle cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sickle cell disease (SCD) patients receiving specific treatment
Study: 33735389
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (200 mg testosterone cypionate injected intramuscularly every 2 weeks for 18 months)
Study: 33737338
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OAd-MSCs plus G-CSF
Study: 33737646
Drug: Infrequent iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrequent iron supplement treatment
Study: 33737646
Drug: Hb 10.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hb 10.6 g/dL cutoff
Study: 33737935
Drug: Intravenous rhC1-INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rhC1-INH 50 U/kg (maximum, 4,200 U)
Study: 33737935
Drug: Pre-treatment phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment phase (no rhC1-INH)
Study: 33737954
Drug: Daclizumab beta
Normalized name: Daclizumab beta
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab beta 150 mg subcutaneously every 4 weeks for up to 5 years
Study: 33738491
Drug: Adjuvant Ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Ozone Therapy
Study: 33738668
Drug: Vorolanib (X-82),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, combined with everolimus.
Study: 33738668
Drug: Everolimus (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (doses >5 mg).
Study: 33739292
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence program lasting 6 months
Study: 33739292
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence program lasting 12 months
Study: 33739292
Drug: Electronic monitors
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic monitors and pill counts for assessing medication adherence
Study: 33739857
Drug: Glofitamab (0.005-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab (0.005-30 mg)
Study: 33740052
Drug: Mannitol excretion
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol excretion at 6 months
Study: 33740157
Drug: Aminoglycoside therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside therapy (amikacin, gentamicin, tobramycin)
Study: 33740205
Drug: Omission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of surgery in complete responders to neoadjuvant chemotherapy
Study: 33740902
Drug: Eptinezumab 300
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptinezumab 300 mg by 30-min intravenous administration every 12 weeks for up to 8 doses
Study: 33740903
Drug: ADHD- (medication-naïve)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD- (medication-naïve)
Study: 33741071
Drug: Theory-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theory-based intervention consisting of an online video and patient recall process for medication reviews.
Study: 33741296
Drug: Eribulin 1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.1 mg/m² in combination with avelumab
Study: 33741296
Drug: Avelumab (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (fixed dose)
Study: 33741317
Drug: TAK-062 (100-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-062 (100-900 mg)
Study: 33741442
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) 8, 10, 12, or 18 mg/kg on days 1 and 8 of 21-day cycles until disease progression or unacceptable toxicity
Study: 33741467
Drug: Deep regional
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep regional hyperthermia scheduled twice weekly
Study: 33741641
Drug: Gastric per-oral
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric per-oral endoscopic myotomy (G-POEM)
Study: 33741670
Drug: Hypothetical participation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical participation in an early phase CAR-T cell therapy trial
Study: 33742104
Drug: Tumor genomic
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor genomic profiling and targeted agents
Study: 33742208
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement with social and behavior change communication intervention
Study: 33743073
Drug: Metronomic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic oral vinorelbine (VRL; 30 mg/day)
Study: 33743128
Drug: Intraoperative photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative photodynamic therapy (PDT) after 5-aminolevulinic acid (5-ALA) administration and maximal resection
Study: 33743171
Drug: Standard-dose P-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose P-T (4.5 g every 6 h)
Study: 33743171
Drug: High-dose P-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose P-T (up to 6.75 g or 9 g every 6 h)
Study: 33743171
Drug: High-dose P-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose P-T
Study: 33743238
Drug: Onasemnogene abeparvovec
Normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Onasemnogene abeparvovec (1·1×10^14 vg/kg) administered as a one-time intravenous infusion.
Study: 33743541
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy (cART) for HBV-HIV co-infection
Study: 33743801
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose vitamin D3 (400 IU daily for 24 weeks)
Study: 33743801
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D3 (3200 IU daily for 12 weeks then 800 IU daily for 12 weeks)
Study: 33743801
Drug: Biochemical monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biochemical monitoring (25-hydroxyvitamin D, corrected calcium, albumin, parathyroid hormone, hepcidin, other vitamin D metabolites, iron studies, C-reactive protein)
Study: 33745032
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CHK1 inhibitor prexasertib (105 mg/m2) and anti-PD-L1 antibody LY3300054
Study: 33745032
Drug: Anti-PD-L1 antibody
Normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Pacmilimab (DB18873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-L1 antibody LY3300054 (Arm A)
Study: 33745032
Drug: CHK1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHK1 inhibitor prexasertib (Arm B)
Study: 33746047
Drug: Recent cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent cytotoxic chemotherapy
Study: 33746047
Drug: Specific anticancer
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific anticancer therapies (e.g. R-CHOP, platinum combined with etoposide, DNA methyltransferase inhibitors)
Study: 33746446
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both DIA and CCE
Study: 33748440
Drug: Selumetinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (50 mg orally twice daily) starting 7 days prior to thoracic radiotherapy and continuing during radiotherapy (6-6.5 weeks; 60-66 Gy/30-33 fractions)
Study: 33748842
Drug: Prophylactic ACEi
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic ACEi treatment
Study: 33748921
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab 600 mg fixed dose plus intravenous pertuzumab (loading dose: 840 mg/kg; maintenance: 420 mg/kg) and docetaxel (≥ 6 cycles; initial dose 75 mg/m2)
Study: 33748921
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab plus intravenous pertuzumab and docetaxel
Study: 33749049
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) 1,000 mg/m²
Study: 33749049
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) + Metformin
Study: 33749049
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) + Melatonin + Metformin
Study: 33749393
Drug: Wells score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wells score with thromboprophylaxis (AC treatment for ⩾ 72 hours or long-term anticoagulation)
Study: 33749616
Drug: Home-Based Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-Based Exercise Therapy (HBET) using wearable technology and elastic band resistance exercises, 3 walking sessions and 2 resistance exercise sessions per week for 4 weeks.
Study: 33749616
Drug: Home-Based Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-Based Exercise Therapy (HBET)
Study: 34637151
Drug: Abrocitinib 200
Normalized name: abrocitinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrocitinib 200 mg oral dose
Study: 33750196
Drug: Last prior
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Last prior therapy
Study: 33750432
Drug: XAV-19 (polyclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: XAV-19 (polyclonal humanized anti-SARS-CoV2 antibodies) administered intravenously, dosage and duration not specified.
Study: 33750454
Drug: ED-initiated buprenorphine
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED-initiated buprenorphine (BUP) with referral for treatment of OUD
Study: 33752251
Drug: Remote intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote intervention including three weekly phone calls and regular follow-up calls.
Study: 33753433
Drug: Serological testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serological testing for anti-hepatitis A virus, hepatitis B surface antigen, hepatitis B surface and core antibody
Study: 33753457
Drug: Pacritinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacritinib combined with Sirolimus and Low-Dose Tacrolimus (PAC/SIR/TAC)
Study: 33753457
Drug: Pacritinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacritinib (100 mg daily, 100 mg twice daily, 200 mg twice daily)
Study: 33753460
Drug: Quarterly syndromic
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarterly syndromic diagnosis and treatment for STI, HIV testing, peer-led counselling and support, provision of condoms and lubricants.
Study: 33754187
Drug: Niraparib 200
Normalized name: niraparib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg with AAP
Study: 33754187
Drug: Niraparib 300
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 300 mg with AAP
Study: 33754187
Drug: Niraparib 200
Normalized name: niraparib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg with apalutamide
Study: 33754317
Drug: Moderate/highly anticholinergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate/highly anticholinergic medications
Study: 33754642
Drug: Ibrutinib (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (840 mg)
Study: 33754642
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg and 840 mg)
Study: 33755155
Drug: Dried serum
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried serum spots (DSS) with an oral dose of 0.4 mg [13C10]retinyl acetate
Study: 33756515
Drug: Volumetric modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volumetric modulated arc therapy (VMAT)
Study: 33757307
Drug: Guideline-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed therapy
Study: 33757307
Drug: β-blocker and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker and device therapies
Study: 33757459
Drug: Nivolumab/ipilimumab combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab/ipilimumab combination therapy (Ipilimumab administered once on Day 1; Nivolumab administered on Day 1 and Day 22 for a total of two 21-day cycles).
Study: 33757581
Drug: Transcranial rotating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial rotating permanent magnet stimulator (TRPMS) treatment, 10 sessions of 40 minutes each.
Study: 33757788
Drug: Adherent patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherent patients (≥80% drug intake)
Study: 33757788
Drug: Non-adherent patients
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adherent patients (<80% drug intake)
Study: 33757788
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with ≥9 co-medications
Study: 33757987
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CDK4/6 inhibitor palbociclib, immune checkpoint inhibitor pembrolizumab, and aromatase inhibitor letrozole (palbo+pembro+AI)
Study: 33757987
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitor pembrolizumab and aromatase inhibitor letrozole (pembro+AI)
Study: 33762025
Drug: Beta-lactam therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam therapeutic drug monitoring (TDM) implementation phases (not yet implemented, partially implemented, fully implemented)
Study: 33762226
Drug: Balanced energy-protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced energy-protein (BEP) supplement and iron/folic acid (IFA) tablets
Study: 33762226
Drug: Iron/folic acid
Normalized name: iron/folic acid 150 mg-1 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron/folic acid (IFA) tablets only
Study: 33762234
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention including physical and laboratory assessment, individualised CV risk assessment, education, treatment recommendations, prescription adaptation, regular communication with treating physician(s), and monthly follow-up for 6 months.
Study: 33762322
Drug: Ad5 PSA/MUC-1/brachyury
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5 PSA/MUC-1/brachyury vaccine
Study: 33762734
Drug: Vaccine targeting
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine targeting mutant IDH1
Study: 33763241
Drug: Intrathecal rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intrathecal rituximab (20 mg, IT)
Study: 33763241
Drug: Intravenous +
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous + Intrathecal (IV+IT)